Abstract

Skeletal muscle atrophy occurs in several pathological conditions, such as cancer, especially during cancer-induced cachexia. This condition is associated with increased morbidity and poor treatment response, decreased quality of life, and increased mortality in cancer patients. A leucine-rich diet could be used as a coadjutant therapy to prevent muscle atrophy in patients suffering from cancer cachexia. Besides muscle atrophy, muscle function loss is even more important to patient quality of life. Therefore, this study aimed to investigate the potential beneficial effects of leucine supplementation on whole-body functional/movement properties, as well as some markers of muscle breakdown and inflammatory status. Adult Wistar rats were randomly distributed into four experimental groups. Two groups were fed with a control diet (18% protein): Control (C) and Walker 256 tumour-bearing (W), and two other groups were fed with a leucine-rich diet (18% protein + 3% leucine): Leucine Control (L) and Leucine Walker 256 tumour-bearing (LW). A functional analysis (walking, behaviour, and strength tests) was performed before and after tumour inoculation. Cachexia parameters such as body weight loss, muscle and fat mass, pro-inflammatory cytokine profile, and molecular and morphological aspects of skeletal muscle were also determined. As expected, Walker 256 tumour growth led to muscle function decline, cachexia manifestation symptoms, muscle fibre cross-section area reduction, and classical muscle protein degradation pathway activation, with upregulation of FoxO1, MuRF-1, and 20S proteins. On the other hand, despite having no effect on the walking test, inflammation status or muscle oxidative capacity, the leucine-rich diet improved muscle strength and behaviour performance, maintained body weight, fat and muscle mass and decreased some protein degradation markers in Walker 256 tumour-bearing rats. Indeed, a leucine-rich diet alone could not completely revert cachexia but could potentially diminish muscle protein degradation, leading to better muscle functional performance in cancer cachexia.

Highlights

  • Skeletal muscle atrophy occurs in several pathological conditions such as cancer, especially during cancer cachexia

  • The cachexia state resulting from Walker 256 tumour growth led to impaired muscle function, which was assessed in this present study by walking, behavioural, and strength tests (Supplementary Figures S1 and S2)

  • Cancer cachexia is characterised by a significant involuntary body weight loss, mainly related to skeletal muscle loss [3,26]

Read more

Summary

Introduction

Skeletal muscle atrophy occurs in several pathological conditions such as cancer, especially during cancer cachexia. This condition is associated with a decrease in treatment response, reducing quality of life and increasing morbidity and mortality in cancer patients [1,2]. Cancer cachexia is a multifactorial syndrome consisting of involuntary body weight loss, especially by skeletal muscle and adipose tissue loss, reduced food intake, elevated resting energy expenditure, excess catabolism, and inflammation [3]. Skeletal muscle atrophy is the main problem of cancer cachexia due to its expressive contribution to total body composition. Skeletal muscle mass counts for up to 50% of total body protein in healthy individuals [4].

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call